Using bilastine in treatment of patients with chronic idiopathic urticaria

Dmitruk V.S.; Denisov A.A.; Khardikova S.A.; Martynova V.G.; Protasevich A.A.; Belyalova I.G.

doi:https://doi.org/10.17116/klinderma20181704151

Dmitruk V.S.

State educational institution of higher professional education "Siberian State Medical University", Russian Ministry of Health and Social Development, Tomsk

ORCID: 0000-0002-8923-1731

Denisov A.A.

Siberian State Medical University, Tomsk

Khardikova S.A.

Siberian State Medical University, Tomsk

Martynova V.G.

Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia

Protasevich A.A.

Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia

Belyalova I.G.

Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia

Using bilastine in treatment of patients with chronic idiopathic urticaria

Authors:

Dmitruk V.S., Denisov A.A., Khardikova S.A., Martynova V.G., Protasevich A.A., Belyalova I.G.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2018;17(4): 51‑57

DOI: 10.17116/klinderma20181704151

Read: 13586 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Dmitruk VS, Denisov AA, Khardikova SA, Martynova VG, Protasevich AA, Belyalova IG. Using bilastine in treatment of patients with chronic idiopathic urticaria. Russian Journal of Clinical Dermatology and Venereology. 2018;17(4):51‑57. (In Russ.)
https://doi.org/10.17116/klinderma20181704151

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective — the study was aimed at assessing the efficacy of bilastine, a modern type 1 histamine receptor blocker, in patients with chronic idiopathic urticaria. Material and methods. We followed 51 patients with chronic idiopathic urticaria. The average age of the patients was 36.4±3.4 years, the duration of the disease was several months to 12 years (the group-average duration was 3.3±1.5 years). Results. All patients often had recurrent urticaria (more than four exacerbations per year, an average of 5.1±1.0 times). The main sensitizing factors include domestic (36.7%), food (13.4%), and epidermal (11.9%) allergens. In most patients with chronic urticaria, exacerbations were associated with concomitant somatic pathology dominated by diseases of the gastrointestinal tract (25.4%), endocrine system (23.5%), and ENT organs (17.6%). All patients received treatment: bilastine at a dose of 20 mg/day (group 1) and 40 mg/day (group 2) for 15 days. Conclusions. The obtained data demonstrate high clinical efficacy and safety of Bilastine in patients with chronic idiopathic urticaria.

Keywords:

chronic idiopathic urticaria

bilastine

H1-blockers

Authors:

Dmitruk V.S.

State educational institution of higher professional education "Siberian State Medical University", Russian Ministry of Health and Social Development, Tomsk

ORCID: 0000-0002-8923-1731

Denisov A.A.

Siberian State Medical University, Tomsk

Khardikova S.A.

Siberian State Medical University, Tomsk

Martynova V.G.

Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia

Protasevich A.A.

Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia

Belyalova I.G.

Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia

Close metadata

References:

Kozel M, Sabroe R. Chronic Urticaria. Aetiology, management and current and future treatment options. Drug. 2004;64:2516-2536.
Ring J, Brockow K, Ollert M, Engst R. Antihistaminesin urticaria. Clin Exp Allergy. 1999;29(Suppl. 11):31-37.
Gaig P, Garcia-Ortega P, Enrique E, Richart C. Successful treatment of chronic idioÂpathic urticaria associated with thyroid autoimmunity. J lnvestAlergol Clin lmmunol. 2000;10:342-345.
Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin lmmunol. 2003;111(2 Suppl):460-475.
Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACl/GA2LEN/EDF guideline: management of urticaria. Allergy. 2006;61:321-331.
Oâ€™Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197.
Gervazieva VB, Rakhmatullina IM, Sibgatullina NA, Clinical and immunological features of chronic recurrent urticaria. Kazanskiy meditsinskiy zhurnal.2003;2:127-131. (In Russ.)
Heymann WR. Chronic urticaria .and angioedema associated With thyroid autoimmunity: review and therapeutic implucations. J Am Acad Dermatol.1999 Feb;40(2Ptl):229-232.
Ryhal B, Demera RS, Choenfeld Y, Peter JB, Gershwin ME. Are autoantibodies present in patients with subacute and chronic urticaria? J Invest Clin lmmunol. 2001;11:16-20.
Montoro J. Effect of H1 antihistamints upon the central nervous system. J Invest Allergol Clin lmmunol. 2006;16(Suppl 1):24-28.
Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FeRl or anti-lgE autoantibodies. J Am Acad Dermatol. 1999;40:443-450.
Zauli D, Deleonarid G, GoderaroS et a. Thyroid autoimmunity in chronic urticarial. Alergy Asthma Proc. 2001;22:93-95.
Instrukciya po primeneniyu lekarstvennogo preparata Niksar dlya medicinskogo primeneniya. Soglasovana MZ RF 14.07.2016. (In Russ.)
Kuna P, Bachert C, Nowacki Z et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009;39(9):1338-1347.
Lucero ML, Gonzalo A, Mumford R et al. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol. 2012;35(Suppl. 1):18-24.
Zuberbier T, Greaves MW, Juhlin L, Mark H, Stingl G, Henz BM. Management of urticaria: a consensus report. J lnvest Dermatol Symp Proc. 2001;6:128-131.
Yanai K, Rogala B, Chugh K et al. Safety considerations in the management of allergic diseases: focus on antihistamines. Curr Med Res Opin. 2012;28(4):623-642.
Garcia-Gea C, Martinez J, Ballester MR, et al. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive- controlled and placebo-controlled phase I clinical trials. Hum Psychopharmacol. 2014;29(2):120-132.
Omen S, Theunissen FL, Van Oers AG, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. Psychopharmacol. 2011;25:1517-1523.
Holgate ST, Canonica GW, Simons FE et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy. 2003;33(9):1305-1324.
Cheburkin AA. Chronic recurrent urticaria: a syndrome or a disease? RMZh. 2011;19(22):1342-1347. (In Russ.)
Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001;40:72-76.
Leurs R, Church MK, Taglialatela M. H₁-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32(4):489-498.
Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64(1):158-165.
Sologuren A, Crean C, Veliente R, McLeverty D. The drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol